NASDAQ: FGENFibrogen Inc Stock
$1.27-0.03 (-2.31%)
Updated Apr 17, 2024
FGEN Price
$1.27
Fair Value Price
N/A
Market Cap
$125.44M
52 Week Low
$0.33
52 Week High
$20.73
P/E
-0.43x
P/B
-0.61x
P/S
0.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$147.75M
Earnings
-$284.23M
Gross Margin
87.2%
Operating Margin
-181.86%
Profit Margin
-192.4%
Debt to Equity
-2.87
Operating Cash Flow
-$315M
Beta
1.4
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
FGEN Overview
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FGEN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FGEN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
FGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more FGEN due diligence checks available for Premium users.
Be the first to know about important FGEN news, forecast changes, insider trades & much more!
FGEN News
Valuation
FGEN fair value
Fair Value of FGEN stock based on Discounted Cash Flow (DCF)
Price
$1.27
Fair Value
$2.96
Undervalued by
57.12%
FGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.43x
Industry
15.83x
Market
41.64x
FGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.61x
Industry
5.83x
FGEN's financial health
Profit margin
Revenue
$27.1M
Net Income
-$56.2M
Profit Margin
-207.2%
FGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FGEN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$423.5M
Liabilities
$585.7M
Debt to equity
-2.87
FGEN's short-term assets ($331.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FGEN's long-term liabilities ($368.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.3M
Investing
$10.2M
Financing
-$246.0k
FGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FGEN vs Biotech Stocks
Fibrogen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.